Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Organon & Co. OGN said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion. According to the terms of the agreement, ...

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Organon & Co. (NYSE:OGN) is one of the ...

Shareholders of Organon & Co (Symbol: OGN) looking to boost their income beyond the stock's 1.2% annualized dividend yield can sell the January 2028 covered call at the $10 strike and collect the ...

The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn ...

What the TOFIDENCE approval means for Organon stock The latest catalyst for Organon (OGN) is the FDA approval of a supplemental Biologics License Application for TOFIDENCE, which broadens its use to ...

Organon ( (OGN)) has provided an announcement. At its 2026 annual meeting held on June 9, 2026, Organon stockholders elected ten board nominees to serve until the 2027 meeting, with each director ...

Stock index futures edged lower on Monday as investors balanced cautious optimism ahead of this week's Big Tech earnings bonanza against ongoing uncertainty from the U.S.-Iran conflict. With five ...

Looking ahead to 2030, our model projects OGN could trade at an average price of $27.19, with a potential range between $20.39 and $33.99. This represents a potential 101.3% return from today's price.

Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?